Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

04 juin 2026 08h55 HE | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness

Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen’s previously published antiviral research Discussion highlights Ampligen’s...
01 juin 2026 08h58 HE | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones

OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a significant milestone in its pancreatic cancer development program,...
27 mai 2026 08h47 HE | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration

Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola Company to release Virtual...
20 mai 2026 15h02 HE | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered direct...
19 mai 2026 08h02 HE | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities

OCALA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a significant increase in stockholder equity and that the Company has...
14 mai 2026 08h41 HE | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer

Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary...
08 mai 2026 08h40 HE | Source: AIM ImmunoTech Inc.

AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds

OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development of...
07 mai 2026 08h23 HE | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

OCALA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the Final Primary Endpoint Report on Objective Response Rate data from...
16 avr. 2026 09h00 HE | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP

Company to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the event here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc....
13 avr. 2026 18h00 HE | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Provides Routine Update on Annual Filings

OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the fiscal year...

Page suivante